Immunovant reports Q4 net loss $75.3M, cash $635M; plans 4-5 registrational IMVT-1402 studies by 2025

Immunovant, Inc.

2024-FY EPS reported -$1.88

Net loss $75.3M ($0.52/sh) for Q4 FY2024 vs $59.4M ($0.46/sh) YoY; FY net loss $259.3M ($1.88/sh).
Cash and equivalents $635M as of March 31, 2024; R&D expenses $66.1M in Q4.
Following FDA Type B meeting, on track to initiate 4-5 registrational studies for IMVT-1402 by March 31, 2025.
Batoclimab MG topline results expected by end of fiscal 2025; CIDP trial extended ~2 quarters before unblinding.
Composition-of-matter patent for IMVT-1402 issued with term through June 2043.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.